Under 10% of individuals eligible to benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it releases its inaugural guidance on the medications.
Given over a billion people worldwide now living with obesity, it is advocating for increased and just access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The latest guidance acknowledges that obesity is a lifelong illness that can be managed with holistic and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major hurdles to universal availability to the jabs that can assist patients in reducing considerable body mass, says the body.
Skinny Jab Shortage
Even in the current most favorable outlook, the supply of these medications might only reach approximately 100 million people – less than 10% of those who need them, per the health organization.
The recommendation urges governments and firms to expand availability, by strategies like patent sharing.
The intellectual property rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Drugs Function
These medications mimick a body's own hormone to reduce digestion speed, suppress the appetite and boost the sense of being full so users eat less.
People typically begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Research points to patients may regain a significant portion after a year of discontinuing the drug, when their typical hunger resume.
To be overweight or obese increases your likelihood for contracting diseases, including type 2 diabetes, heart disease, stroke, and specific cancers.
Excess weight concerns individuals in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the health agency.
